Academic Study Boosts Belief In TIL Therapies, Including Iovance’s Lifileucel
Company Has Begun Rolling Submission
Executive Summary
A new academic study presented at ESMO has provided the first Phase III data for tumor-infiltrating lymphocytes as a potential new therapeutic class, while industry leader Iovance looks set to have early-stage data for its TIL accepted by the US FDA.
You may also be interested in...
Iovance To Press Ahead With Melanoma Cell Therapy Filing Despite Doubters
Iovance has seen its share price collapse after releasing data from a second melanoma patient cohort – but is confident its potential first-in-class therapy is approvable.
Lessons Learnt From Aduhelm, Eisai Is Preaching Patience On Alzheimer’s Drug Leqembi
Eisai has spent 25 years looking for a breakthrough in Alzheimer’s and warns that healthcare systems need to undergo a major shift to accommodate its breakthrough drug.
Pfizer Takes First Small Step Into Longevity Field With Gero Collaboration
Interest in longevity and anti-aging is gathering momentum, and Pfizer has dipped its toe in the water with an early-stage drug discovery partnership.